177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer Clinic of Endocrinology, Inst. of Nuclear Medicine, University Hospital,

Slides:



Advertisements
Similar presentations
Progress Against Stomach Cancer. 1980–1989 Progress Against Stomach Cancer 1980– : Combination chemotherapy improves outcomes for advanced stomach.
Advertisements

Case 20 Thomas J. Giordano, M.D., Ph.D.. History A 54-year old man with a past medical history of goiter for approximately 4 years was followed by ultrasound.
Herceptin as a Phase 0 Imaging Example. Phase 0 Trials in Oncology Drug Development Steven M. Larson, M.D. Nuclear Medicine Svc, Department of Radiology.
Hong CM, Ahn BC, Jeong SY, Lee SW, Lee J
Frank P. Dawry Thyroid Cancer Therapy Radioactive Iodine (I-131)
Lower Gastrointestinal NET Clinical case One patient and how many doctors ? Dimitrios Dimitroulopoulos MD, PhD Consultant Gastroenterology Dpt. “Agios.
Radioactive Iodine Refractory Patients : Definition and Treatment of Radioactive Iodine Refractory Thyroid Cancer Patients 방사성 옥소치료에 내성을 가진 갑상선암의 진단과 치료에.
Carcinoma scarsamente differenziato Terapia radiorecettoriale
Modified Megestrol The Clinical Trials by : Carolina R. Akib
Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression Lindstrom LS et al. Proc SABCS 2010;Abstract S3-5.
Radionuclide methods in oncology Otto Lang, MD, PhD Otakar Bělohlávek, MD, CSc Dept Nucl Med Charles Univ, 3rd Med Fac Materials for medical students.
Introduction to Nuclear Medicine
Colorectal Cancer Center Jena Introduction In Germany, there are currently approximately newly diagnosed patients with colorectal carcinoma.
Breast cancer patient pathway
Update on 18 F-Fluorodeoxyglucose/Positron Emission Tomography and Positron Emission Tomography/ Computed Tomography Imaging of Squamous Head and Neck.
Molecular Cancer Targets Wester H Clin Cancer Res 2007;13:
Integrated PET/CT in Differentiated Thyroid Cancer: Diagnostic Accuracy and Impact on Patient Management J Nucl Med 2006; 47:616–624 報告者 : 蘇惠怡.
The Detection of Bone Metastases in Patients with High-Risk Prostate Cancer: 99 mTc-MDP Planar Bone Scintigraphy, Single- and Multi-Field-of-View SPECT,
International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY.
Improving Access to Musculoskeletal Services: A New Model of Care Ian Holding Senior Lecturer Musculoskeletal Medicine, Otago BSc, MBBCh, FRNZCGP, Dip.
Therapeutic Education: Cancer Patients on chemotherapy: Shamim Akhter QURESHI MBBS,MPH, Ingénieur d’étude(EHESP) 2 nd June 2012 June 2010.
Casefinding & Follow-Up Dolores E. McCord, RHIT, CTR Piedmont Hospital Atlanta, Georgia.
Meeting goals Provide participants – Current status regarding Classification Diagnosis Management – Update on the latest developments in neuroendocrine.
Leila Moghaddam Banaem In diagnosis radiopharmaceuticals produce images that enable the function and living chemistry of the body to be evaluated. Radiopharmaceuticals.
Objectives Abstract Background Materials & Methods References 1.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of.
Corporate Employee Benefits: Medical Insurance Programme
radio-iodinated metaiodobenzylguanidine (123I-MIBG)
Angiogenesis ↓ Metastasis. Angiogenesis--- The process of developing new blood vessels. Cancer cells (probably like all tissues) secrete substances that.
Radioisotopes in diagnostics and therapy (pre-)clinical view Radboud University Nijmegen Medical Center, The Netherlands Otto C. Boerman.
ACRIN 6685 Overview ACRIN 6685 A Multi-center Trial of FDG-PET/CT Staging of Head and Neck Cancer and its Impact on the N0 Neck Surgical Treatment in Head.
Photo: Trym I. Bergsmo. Best and worst cases Sameline Grimsgaard MD MPH PhD National research center in complementary and alternative medicine; NAFKAM.
The Colorectal Cancer Center Jena Gharbi A, Settmacher U. Department of General, Visceral and Vascular Surgery, Friedrich-Schiller-University Jena
Octreoscan Radiolabled Somatostatin Analog. What Is Somatostatin?  Somatostatin is a naturally occurring neuropeptide found in the hypothalamus that.
PROTOCOL GO29294 A study evaluating a potential new treatment for locally advanced or metastatic urothelial bladder cancer VERSION 1 | 19 SEPTEMBER 2014.
CHIEF EXECUTIVE’S BRIEFING Tom Taylor Chief Executive 23 rd May 2006.
NeoTect Tc99m Depreotide Injection. NeoTect  Approved by the FDA - August 3, 1999  Used in Imaging Pulmonary Masses  Normal activity in high concentrations.
Consent for Research Study A study for patients newly diagnosed with advanced glioblastoma (brain cancer): Learning whether a PET scan with F-fluoromisonidazole.
Verluma Nofetumomab Merpentan (Fragment). Indications For the detection and staging of previously untreated small cell lung cancer. It must be confirmed.
MABEL – a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan H Wilke, R Glynne-Jones, J Thaler,
1. Clinical Impression? Differentials?. Thyroid Carcinoma commonly manifests as a painless, palpable, solitary thyroid nodule The patient's age at presentation.
VCU NMT Program Adrenal Scintigraphy Aldosteronism Addison’s Cushing’s Virilizing Adenomas Pheochormocytomas Neuroblastomas Adrenal Cortical Pathologies:
Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma JIN Chen, YAO Lie, LONG.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.
Presented at the NAACCR Annual Conference Quebec City June 22, 2010.
CANCER THERAPY  Surgery  Radiation Therapy  Chemotherapy  Stem Cell Transplant  Immunotherapy  Targeted Therapy  Hormone Therapy  Precision Medicine.
HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.
231 Unusual coexistence of differentiated thyroid cancer and thyrotropin- producing pituitary microadenoma: a case report 1 Muni A., 1 Rouhanifar H., 1.
Date of download: 7/11/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Stimulation With 0.3-mg Recombinant Human Thyrotropin.
Date of download: 9/18/2016 From: Somatostatin Receptor Scintigraphy: Its Sensitivity Compared with That of Other Imaging Methods in Detecting Primary.
Date of download: 10/7/2017 Copyright © ASME. All rights reserved.
Upfront Combination Therapy vs Step-Up Approach for PAH:
BREAST CANCER ONCOLOGY NAVIGATION SERVICE
Coordination (benign lesions)
TREATMENT ARM B: Cycles 1–3: Cycles 4+: 5-FU continuous infusion
Peptide Receptor Radionuclide Therapy PRRT
Radioiodine scintigraphy of a patient with thyroid cancer shows abnormal 123I uptake in the neck and chest corresponding to iodine-avid metastases in the.
Radiolabled Somatostatin Analog
Nofetumomab Merpentan (Fragment)
VCU NMT Program Adrenal Scintigraphy
Project Title Name Contact .
M.Carsote 1,2, A.Geleriu 2, R.Miron 3, C.Ene2,
Oncology Market Forecast
Radiolabled Somatostatin Analog
Breast Sentinel Node Scintigraphy
The Road to Quality Improvement in HER2-Positive Breast Cancer
Nat. Rev. Clin. Oncol. doi: /nrclinonc
The Genetic Basis for Cancer Treatment Decisions
CoPrincipal Investigators
Nuclear medicine.
Presentation transcript:

177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer Clinic of Endocrinology, Inst. of Nuclear Medicine, University Hospital, Basel, CH For Questions contact: Beat Müller, Martin A. Walter,

Medullary Thyroid Cancer Treatment Options: -Surgery (first line) -To date no effective systemic treatment option -Radiation Therapy is not well defined -Treatment options with different Radiopeptides are currently evaluated

Aim To assess the value of 177 Lu-Dota-NOCate and 177 Lu-Dota-Gastrin in Imaging and Treatment of Metastatic Medullary Thyroid Cancer Ethically Approved (EKBB)

Radiopeptides Target Somatostatin/ CCK2-Receptor Ligand Somatostatin/ Gastrin-Analogs Signal 177 Lu

„Magic Bullet“ Approach ApplicationDistributionAccumulation Tumor Metastases

Affinity Profile (Dota-NOC-ATE)

Receptor Profile (MTC) EB Forssell-Aronsson. J Nucl Med 2000;41:636–642

Pilot-Patient (Dota-NOC-ATE) Specific Tumor Uptake (LN-metastesis) p9581 ♂, 63y Metastised MTC

Patients Patients with progressive MTC Exclusion criteria: Karnofsky Performance Status < 50% Refusion of a 1-year contraception Pregnancy Breast-feeding Age<18

Diagnostic Scintigraphy Scintigraphy + Dosimetry (first compound, outpatient, 2d) Scintigraphy + Dosimetry (second compound, outpatient, 2d) 2 weeks later Significant Accumulation + Favorable Biodistribution → Treatment

Treatment Inpatient 3 Days Day 1: Injection of Radiopeptide + Amino Acid Infusion (Kidney Protection) Day 2: Imaging Day 3: Release of Patient

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.